Wednesday, August 12, 2026

Labcorp agrees to pay $14.5 million for alleged Medicare testing fraud

Labcorp will pay $14.5 million following allegations it billed Medicare for unnecessary urine drug tests between 2018 and 2023. Federal
X / Twitter
LinkedIn
Print

Laboratory Corporation of America, known as Labcorp, has agreed to pay $14.5 million to resolve allegations that it violated the False Claims Act by submitting medically unnecessary claims for urine drug testing to Medicare for payment, according to a July 15 announcement.

Labcorp offered a testing panel called “Toxassure Comprehensive,” which included both Presumptive and Definitive urine drug tests. The company admitted that from Jan. 1, 2018 through Nov. 22, 2023, it routinely submitted claims to Medicare for both types of tests—sometimes on the same patient and date using the same sample—and billed with codes CPT 80307 and HCPCS G0483 each time it performed the ToxAssure Comprehensive panel. For several substances tested directly with Definitive methods, a Presumptive option existed but was not used first.

The government alleges this conduct led Labcorp to bill Medicare for medically unnecessary tests. United States Attorney Leah B. Foley said, “Today’s settlement reflects my Office’s enduring commitment to combatting healthcare fraud and recovering taxpayer money. Labcorp’s conduct resulted in Medicare payouts for unnecessary tests. We will continue to hold accountable providers who engage in fraud, waste, and abuse.” Assistant Attorney General Brett A. Shumate added, “The government expects that any testing it pays for is medically necessary and not wasteful or structured in a way that maximizes billing opportunities for providers at the expense of the federal fisc.”

Acting Deputy Inspector General Miranda L. Bennett of the Department of Health and Human Services Office of Inspector General said, “Medicare beneficiaries and taxpayers should be able to trust that testing and billing practices are fair and appropriate… when providers put profits before patients and ignore billing rules, we will act decisively to hold them accountable.”

As part of the settlement agreement, Labcorp represented that it has stopped billing this combination of codes for urine drug testing using its ToxAssure Comprehensive panel. The company received credit under Department of Justice guidelines regarding disclosure, cooperation, and remediation in False Claims Act cases.

The U.S. Attorney’s Office for the District of Massachusetts serves all residents in Massachusetts through prosecutions involving national security threats, civil rights violations, community initiatives on civil rights advancement and violence prevention; maintains offices across Boston as well as Springfield and Worcester; employs over 200 attorneys along with paralegals; operates as part of the United States Department of Justice, according to its official website.

Filed Under

Share This Story

X / Twitter
LinkedIn
Email
Print

Advertisement

300 × 250

Related

DEA Details Ongoing Operations Against CJNG Cartel

Daily Dispatch

The morning briefing on federal government — delivered to your inbox before 7 AM.

Advertisement

300 × 120

More from Defense

Washington National Guard Continues Statewide Wildfire Response

The Washington National Guard continued deploying air and ground assets across the state on Aug. 10 as multiple wildfires burned simultaneously in the Pacific Northwest. Federal active-duty forces from Joint...

OCC Signals Push to Revive New Bank Charter Applications

The Office of the Comptroller of the Currency announced on Aug. 11 that it will prioritize new bank charter applications as part of a “community bank comeback” initiative. The effort...

FDA Approves First Oral PCSK9 Inhibitor to Lower Cholesterol

The FDA approved the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults on July 17, removing a major barrier to broader use of the most powerful class of...